Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Verona Pharma strengthens commercialization leadership team
August 24, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China
August 19, 2022 02:46 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs
August 15, 2022 16:05 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering
August 10, 2022 20:22 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma plc Announces Proposed Underwritten Public Offering
August 09, 2022 16:16 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022 03:00 ET
|
Verona Pharma plc
Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 ...
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
August 09, 2022 02:00 ET
|
Verona Pharma plc
Statistically significant improvements in key measures of lung function 42% reduction in rate of exacerbations over 24 weeks Well tolerated with safety results similar to placebo Conference call...
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD
August 08, 2022 16:30 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update
July 29, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
June 09, 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...